Biological imaging in radiation oncology

Zeitschrift fur Medizinische Physik

Volumn 15, Issue 3, 2005, Pages 141-145

  Grosu, Anca Ligia ^a   Wiedenmann, Nicole ^a   Molls, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biological imaging; Biological target volume; Dose painting; Radiation treatment planning and monitoring

Indexed keywords

FLUORODEOXYGLUCOSE;

APOPTOSIS; ARTICLE; BRAIN TUMOR; CARCINOGENESIS; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; ESOPHAGUS CARCINOMA; GENE EXPRESSION; HEAD AND NECK TUMOR; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; LUNG CARCINOMA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIATION MONITORING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

EID: 24644449095     PISSN: 09393889     EISSN: None     Source Type: Journal    
DOI: 10.1078/0939-3889-00264     Document Type: Article

References (35)

1. Ling CC, Humm J, Larson S et al.: Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47 (2000) 551-560
2. Grosu AL, Piert M, Weber WA et al.: Positron Emission Tomography in Target Volume Definition for Radiation Treatment Planning. Strahlentherapie und Onkologie 2005 (submitted)
3. Chapman JD, Bradley JD, Eary JF et al.: Molecular (functional) imaging for radiotherapy applications: a RTOG symposium. Int J Radiat Oncol Biol Phys 55 (2003) 294-301
4. Kiffer JD, Berlangieri SU, Scott AM et al.: The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 19 (1998) 167-177
5. Munley MT, Marks LB, Scarfone C et al.: Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 23 (1999) 105-114
6. Nestle U, Walter K, Schmidt S et al.: 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44 (1999) 593-597
7. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG et al.: The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 (2000) 317-324
8. MacManus MP, Hicks RJ, Ball DL et al.: F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 92 (2001) 886-895
9. Giraud P, Grahek D, Montravers F et al.: CT and (IS)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 49 (2001) 1249-1257
10. Mah K, Caldwell CB, Ung YC et al.: The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 52 (2002) 339-350
11. Erdi YE, Rosenzweig K, Erdi AK et al.: Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62 (2002) 51-60
12. Ciernik IF, Dizendorf E, Baumert BG et al.: Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57 (2003) 853-863
13. Bradley J, Thorstad WL, Mutic S et al.: Impact of FDG-PET on radiation therapy volume delineation in NSCLC. Int J Radiat Oncol Biol Phys 59 (2004) 78-86
14. Grosu AL, Weber WA, Feldmann HJ et al.: First Experience with 1-123-Alpha-Methyl-Tyrosine SPECT in the 3-D Radiation Treatment Planning of Brain Gliomas. Int J Rad Oncol Biol Phys 47 (2000) 517-527
15. Grosu AL, Feldmann HJ, Dick S et al.: Implications of IMT-SPECT for postoperative radiation treatment planning in patients with gliomas. Int J Rad Oncol Biol Phys 54 (2002) 842-854
16. Grosu AL, Lachner R, Wiedenmann N et al.: Validation of a Method for Automatic Fusion of CT- and C11-Methionine-PET Datasets of the Brain for Stereotactic Radiotherapy Using a LINAC. First Clinical Experience. Int J Rad Oncol Biol Phys 56 (2003) 1450-1463
17. Grosu AL, Weber AW, Riedel E et al.: L-(Methyl-11C) Methionine Positron Emissions Tomography for Target Delineation in Resected High Grade Gliomas before Radiation Therapy. Int J Rad Oncol Biol Phys 2005 (in press)
18. Pirzkall A, McKnight TR, Graves EE et al.: MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 50 (2001) 915-928
19. Pirzkall A, Li X, Oh J et al.: 3D MRSI for resected high-grade gliomas before RT: Tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 59 (2004) 126-137
20. Grosu AL, Weber WA, Franz M et al.: Re-Irradiation of Recurrent High Grade Gliomas Using Amino-Acids-PET(SPECT)/CT/MRI Image Fusion to Determine Gross Tumor Volume for Stereotactic Fractionated Radiotherapy. Int J Rad Oncol Biol Phys 2005 (in press)
21. Mizowaki T, Cohen GN, Fung AY et al.: Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. Int J Radiat Oncol Biol Phys 54 (2002) 1558-1564
22. Mueller-Lisse UG, Vigneron DB, Hricak H et al.: Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 221 (2001) 380-390
23. Wefer AE, Hricak H, Vigneron DB et al.: Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164 (2000) 400-404
24. Coakley FV, Kurhanewicz J, Lu Y et al.: Prostate cancer tumour volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223 (2002) 91-97
25. Zaider M, Zelefsky MJ, Lee EK et al.: Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 47 (2000) 1085-1096
26. Rischin D, Peters L, Hicks R et al.: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 19 (2001) 535-42
27. Chao KS, Bosch WR, Mutic S et al.: A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
28. Haubner R, Wester HJ, Weber WA et al.: Noninvasive imaging of alpha (v) beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61 (2001) 1781-1785
29. Wagner M, Seitz U, Buck A et al.: 3′-[18F]fluoro-3′- deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res 63 (2003) 2681-2687
30. Belhocine T, Steinmetz N, Li C et al.: The Imaging of Apoptosis with the Radiolabeled annexin V: Optimal Timing for Clinical Feasibility. Technol Cancer Res Treat 3 (2004) 23-32
31. Grosu AL, Piert M, Weber WA et al.: Positron Emission Tomography in Target Volume Definition for Radiation Treatment Planning. Strahlentherapie und Onkologie 2005c (submitted)
32. Weber WA, Petersen V, Schmidt B et al.: Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21 (2003) 2651-2657
33. Mac Manus MP, Hicks RJ, Matthews JP et al.: Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21 (2003) 1285-1292
34. Flamen P, Van Cutsem E, Lerut A et al.: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
35. Grigsby PW, Siegel BA, Dehdashti F et al.: Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 55 (2003) 907-913